EGFR and lung adenocarcinoma: [115] on 1448 lung adenocarcinoma patients found that lung adenocarcinoma patients with PTB receiving targeted drug treatment (EGFR‐TKI) had shorter overall survival than the simple LC group (p < 0.005), with low rates of grade 3/4 adverse reactions in both groups.